Privium Fund Management B.V. Increases Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Privium Fund Management B.V. boosted its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 6.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 266,794 shares of the company's stock after acquiring an additional 16,050 shares during the period. Ionis Pharmaceuticals accounts for about 2.1% of Privium Fund Management B.V.'s portfolio, making the stock its 12th biggest position. Privium Fund Management B.V. owned about 0.17% of Ionis Pharmaceuticals worth $9,327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Victory Capital Management Inc. increased its stake in Ionis Pharmaceuticals by 5.9% in the third quarter. Victory Capital Management Inc. now owns 18,350 shares of the company's stock valued at $735,000 after acquiring an additional 1,020 shares during the last quarter. Quest Partners LLC boosted its holdings in shares of Ionis Pharmaceuticals by 94.8% in the 3rd quarter. Quest Partners LLC now owns 2,674 shares of the company's stock valued at $107,000 after purchasing an additional 1,301 shares in the last quarter. Prospera Private Wealth LLC bought a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $42,000. Commerce Bank raised its holdings in shares of Ionis Pharmaceuticals by 1.6% during the 3rd quarter. Commerce Bank now owns 77,553 shares of the company's stock worth $3,107,000 after buying an additional 1,211 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its position in shares of Ionis Pharmaceuticals by 21.0% during the 3rd quarter. Advisors Asset Management Inc. now owns 6,140 shares of the company's stock worth $246,000 after buying an additional 1,066 shares during the last quarter. 93.86% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IONS shares. StockNews.com upgraded Ionis Pharmaceuticals to a "sell" rating in a research report on Tuesday, March 18th. Citigroup decreased their price target on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Royal Bank of Canada reissued an "outperform" rating and issued a $70.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday, February 20th. BMO Capital Markets cut their target price on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating on the stock in a research report on Thursday, February 20th. Finally, William Blair reiterated an "outperform" rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $59.56.

Insider Buying and Selling

In related news, EVP Patrick R. O'neil sold 6,165 shares of the business's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total value of $194,937.30. Following the completion of the sale, the executive vice president now owns 57,452 shares in the company, valued at approximately $1,816,632.24. The trade was a 9.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Eric Swayze sold 7,154 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $32.84, for a total transaction of $234,937.36. Following the completion of the sale, the executive vice president now directly owns 45,670 shares of the company's stock, valued at $1,499,802.80. The trade was a 13.54 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 111,956 shares of company stock valued at $3,608,439. 2.71% of the stock is owned by insiders.

Ionis Pharmaceuticals Trading Up 0.5 %

IONS traded up $0.18 during trading on Friday, hitting $32.91. 1,999,130 shares of the stock traded hands, compared to its average volume of 1,419,707. The firm has a market capitalization of $5.23 billion, a P/E ratio of -10.83 and a beta of 0.28. Ionis Pharmaceuticals, Inc. has a 12-month low of $30.23 and a 12-month high of $52.34. The firm has a 50-day moving average of $32.62 and a 200 day moving average of $36.26. The company has a debt-to-equity ratio of 2.12, a current ratio of 8.47 and a quick ratio of 8.82.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.46. The company had revenue of $227.00 million for the quarter, compared to the consensus estimate of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. Ionis Pharmaceuticals's revenue for the quarter was down 30.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 EPS. Equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.